Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3584]

Protein disguise could be new target for cancer immunotherapy

Protein disguise could be new target for cancer immunotherapy

Researchers identify how to prevent cancer metastases

Researchers identify how to prevent cancer metastases

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanoma

ASCO 2021: Benefits of immunotherapy combination persist for more than six years in advanced melanoma

How 'paralysed' immune cells can be reactivated against brain tumours

How 'paralysed' immune cells can be reactivated against brain tumours

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small cell lung cancer

ASCO 2021: Immunotherapy delays disease recurrence in patients with early-stage, resected non-small cell lung...

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with advanced melanoma

ASCO 2021: Dual immunotherapy regimen significantly delays disease progression in patients with advanced melanoma

First immune stimulating long noncoding RNA involved in body's response to cancer

First immune stimulating long noncoding RNA involved in body's response to cancer

BGICC consensus and recommendations for the management of triple-negative breast cancer

BGICC consensus and recommendations for the management of triple-negative breast cancer

Nivolumab approved in England for patients with oesophageal cancer

Nivolumab approved in England for patients with oesophageal cancer

Tumour-promoting immune cells retrained to fight most aggressive type of brain cancer

Tumour-promoting immune cells retrained to fight most aggressive type of brain cancer

More from ecancer